Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Anti-fibrotic agent by Boehringer Ingelheim International for Kidney Fibrosis: Likelihood of Approval
Anti-fibrotic agent is under clinical development by Boehringer Ingelheim International and currently in Phase I for Kidney Fibrosis. According to...
Data Insights
Anti-fibrotic agent by Boehringer Ingelheim International for Myocardial Fibrosis: Likelihood of Approval
Anti-fibrotic agent is under clinical development by Boehringer Ingelheim International and currently in Phase I for Myocardial Fibrosis. According to...